We aim to deliver 25 new treatments in our first 25 years


We aim to deliver 25 new treatments in our first 25 years

DNDi Strategic Plan 2021-2028

At DNDi, we use the power of innovation, open science, partnerships, and advocacy to find solutions to a great injustice: the lack of medicines for life-threatening diseases that disproportionately impact poor and marginalized people.

Our research and development (R&D) partnerships have delivered thirteen field-adapted and affordable treatments for six deadly diseases, saving millions of lives.

Our new strategy charts an eight-year journey to 2028, by which time we aim to have delivered 25 new treatments in our first 25 years.

Virtual event

To mark the launch of our new strategy, we were joined by a panel of passionate experts to explore what it will take to deliver medical solutions for neglected patients and build an R&D system that leaves no one behind. 

‘Our vision for global health R&D for the next decade is to contribute to a more equitable system for innovation and access, where we not only address clear treatment gaps for infectious diseases, but also help to drive wider systemic changes needed to ensure access to the fruits of scientific progress for all people in need.’

Dr Bernard Pécoul, Founder, DNDi 

Our commitments

Deliver 15-18 additional treatments

  • 10-12 new treatments from current mature portfolio (2021-24)
  • 5-7 new treatments from earlier-stage NCEs and portfolio expansion (2025-28)

Focus on 5 cross-cuttings strategic imperatives

Deliver new treatments and expand access for neglected patients by addressing R&D gaps for NTDs and viral diseases, including pandemic- prone and climate-sensitive diseases

Join with public health leaders and R&D actors in low- and middle-income countries to advance sustainable innovation ecosystems that address neglected patients’ needs

Contribute to building a proactive agenda for maternal and child health and gender-responsive R&D

Champion open science and transparency

Leverage new technologies to accelerate R&D and access

Drive impact across the 3 pillars of our mission

Lightbulb graphic

Innovate to save lives

  • Deliver 15-18 new treatments
  • Identify 8-10 new drug candidates from discovery efforts
  • Conduct at least 6 new studies on indications for paediatric use
  • Develop strategies tailored to target diseases and countries’ specific needs to ensure equitable and affordable access and delivery of new treatments
Connectors graphic

Foster sustainable solutions

  • Grow partnerships for ‘end-to-end’ R&D in LMICs
  • Proactively collaborate with LMIC pharmaceutical and other partners
  • Conduct half of first-in-human Phase I studies in LMICs
  • Train 600 to 1,000 frontline clinicians and researchers every year
Loudspeaker graphic

Advocate for change

  • Secure concrete changes in key policies to make the innovation system more needs-driven, collaborative, equitable, open and transparent, inclusive, and sustainable
  • Engage with 50+ strategic advocacy partners to build stronger coalitions and more effective networks of influence
  • Document and disseminate key lessons from DNDi’s model

DNDi will deliver 15 to 18 new treatments between 2021 and 2028, for a total of 25 new treatments in our first 25 years

Powering our ambitions

  • We will maintain a diverse workforce and an inclusive culture, which are central to the success of DNDi’s mission and programmes.
  • We will adopt best practices in alliance management to further our strategic partnerships with industry, public health experts, and academia.
  • We will contribute to climate change mitigation – limiting our carbon footprint and working to ‘green’ the pharmaceutical development process wherever possible.
  • We will seek the support of governments, other funding institutions, and private philanthropy to raise EUR 612 million for 2021-2028.

Spending on impact

We keep our overhead low so that we maximize the impact we can have for neglected patients. We aim to keep the ratio of our activities directly related to our social mission (R&D, LMIC partnerships, and advocacy) in line with recent years, where the average was 87%.

A further €612 million investment, to reach 25 treatments in 25 years